Skip to main navigation Skip to search Skip to main content

Updated Treatment of Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report

  • Gülfem E Çelik*
  • , Joanna S Makowska
  • , Maria Jose Torres
  • , Cristobalina Mayorga
  • , Tanya M Laidlaw
  • , Alessandra Vultaggio
  • , Sanna Toppila-Salmi
  • , Ludger Klimek
  • , Aslı Gelincik
  • , Annick Barbaud
  • , Lene H Garvey
  • , Ömür Aydın
  • , Thomas Eiwegger
  • , Katharine M Woessner
  • *Corresponding author for this work

Research output: Journal article (peer-reviewed) › Journal article

Abstract

Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NSAID-ERD) is a heterogeneous condition characterized by chronic eosinophilic airway inflammation in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma whose symptoms are aggravated after ingestion of aspirin and other NSAIDs. As a unique treatment, aspirin treatment after desensitization (ATAD) has been in use for several years after showing the inhibitory effect on CRS symptoms and nasal polyp growth as well as severe asthma. However, in recent years, biologics have also shown to cause a decrease in polyp size as well as associated outcomes such as quality of life. In this manuscript, considerations on choosing the best treatment of NSAID-ERD are laid out based on current literature.

Original languageEnglish
Pages (from-to)2656-2674
Number of pages19
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume81
Issue number8
Early online date05 Feb 2026
DOIs
Publication statusPublished - Aug 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Updated Treatment of Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report'. Together they form a unique fingerprint.

Cite this